GeneralConnection.com ➔ Dictionary
Dictionary Search

savara

Synonyms

Noun

1. Savara

2. Dravidian, Savara

3. South-Central Dravidian

Usage
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim - Yahoo Finance
Savara’s FDA Review Extension Keeps Molgramostim Thesis Intact But Delayed - simplywall.st
Savara gets FDA review extension for lead asset - MSN
[ARS] Savara Inc SEC Filing - Stock Titan
FDA delays decision on Savara’s rare lung disease therapy to November - FirstWord Pharma
Savara Inc ($SVRA) CEO 2025 Pay Revealed - Quiver Quantitative
Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Savara Grants Equity Awards to 24 New Employees - MyChesCo
Savara Inc. ticks higher amid takeover speculation - MSN
Assessing Savara (SVRA) Valuation After Recent Share Price Weakness And Ongoing Losses - simplywall.st
Savara (NASDAQ: SVRA) seeks big share boost and equity plan expansion - Stock Titan
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed - Yahoo Finance
Savara Announces New Employment Inducement Grant - Yahoo Finance
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* - Yahoo Finance
VR Adviser Adds Over 1 Million Savara Shares - Yahoo Finance
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance
George H. Savara - Legacy obituary
FDA Extends Review of Savara’s Molgramostim Application to November - MyChesCo
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - Yahoo Finance
Citizens reiterates Savara stock rating on likely FDA approval - Investing.com
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - Business Wire
A Look At Hercules Capital (HTGC) Valuation After The Expanded Savara Loan Agreement - Yahoo Finance
FY2026 EPS Estimates for Savara Decreased by Lifesci Capital - MarketBeat
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears - Yahoo Finance
Savara to Present Molgramostim Data at ATS 2026 Conference - MyChesCo
What Does Wall Street Think About Savara Inc. (SVRA)? - Yahoo Finance
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance
Savara assumed with an Outperform at Oppenheimer - TipRanks
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
FDA Denies Langhorne-Based Savara Application for Rare Lung Disease Treatment - MSN
Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP - simplywall.st
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance
Savara Announces Participation in 2026 Citizens Life Sciences Conference - Yahoo Finance
SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN
Jefferies sees Savara stock approval odds at 90% for rare lung drug - Investing.com
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
VR Adviser Adds Over 1 Million Savara Shares - The Motley Fool
FDA extends review of Savara’s molgramostim application - Investing.com
Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA) - Seeking Alpha
Man kills tribal couple over suspicion of practising witchcraft in Andhra's Srikakulam - The New Indian Express
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Yahoo Finance
Savara (NASDAQ:SVRA) Stock Price Up 2.5% - Here's Why - MarketBeat
Savara Announces New Employment Inducement Grant - Business Wire
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System - Yahoo Finance
Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough - Yahoo Finance
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants - Yahoo Finance
Savara: Back On Track With Upcoming APAP BLA Filing (NASDAQ:SVRA) - Seeking Alpha
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Savara to present molgramostim data at ATS conference in May - Investing.com
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M - BioSpace
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI - BioSpace
Savara (NASDAQ: SVRA) details new Yardley headquarters lease terms - Stock Titan
Savara Announces New Employment Inducement Grant - February 13, 2026 - BioSpace
Savara Inc. ticks higher amid takeover speculation - MSN
Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update - Business Wire
Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 - BioSpace
Portnoy Law Firm Announces Class Action on Behalf of Savara, Inc. Investors - GlobeNewswire
FDA extends review of Savara’s molgramostim application By Investing.com - Investing.com South Africa
Savara receives European patent for PAP treatment device - Investing.com
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP - TipRanks
Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis - BioSpace
Savara Promotes Dr. Yasmine Wasfi to Chief Medical Officer - Contract Pharma
Savara secures additional $75m in debt financing for potential drug launch - Investing.com
New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
Savara receives FDA priority review for rare lung disease drug - Investing.com
Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 - BioSpace
Savara Says UK Regulator Accepts MOLBREEVI Application - MyChesCo
H.C. Wainwright reiterates Savara stock rating, $10 target - Investing.com
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - The Joplin Globe
Savara stock dives after FDA refuses filing for rare lung disease drug - FirstWord Pharma
Savara’s SWOT analysis: molbreevi’s potential reshapes rare respiratory stock outlook - Investing.com
Savara Inc. (SVRA): Analysts See 212% Upside Potential - Yahoo Finance
135 lbs. Champ. Round 2 - Savara Hanft, Hickman vs Bryah Jackson, Little Rock Central - FloWrestling
Savara Advances MOLBREEVI Reviews in U.S., Europe, U.K. - MyChesCo
FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset - Fierce Pharma
Savara Stock Surges Amid Positive Financial Developments and Raised Price Target - timothysykes.com
Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost - GlobeNewswire
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently - GlobeNewswire
FDA extends review of Savara’s molgramostim application By Investing.com - Investing.com India
Portnoy Law Firm Announces Class Action on Behalf of Savara, Inc. Investors - GlobeNewswire
SVRA Lead Plaintiff Deadline (11/7/25) Reminder: Savara - GlobeNewswire
Savara Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRA - FinancialContent
ROSEN, A LONGSTANDING LAW FIRM, Encourages Savara Inc. - GlobeNewswire
Savara (SVRA) Stock: Why It Could Double (Mini Selloff) 2026-04-20 - Community Volume Signals - Cổng thông tin điện tử tỉnh Tây Ninh
SVRA NOTICE: Savara Inc. Investors Urged to Contact Kirby McInerney LLP About Securities Fraud Lawsuit - GlobeNewswire
Savara Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds - GlobeNewswire
Savara Promotes Yasmine Wasfi, M.D., Ph.D., FCCP To CMO - citybiz
Savara Is Maintained at Market Outperform by JMP Securities - Moomoo
Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost - GlobeNewswire
SVRA NOTICE: Savara Inc. Investors Urged to Contact Kirby McInerney LLP About Securities Fraud Lawsuit - GlobeNewswire
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MyChesCo
Manufacturing issues scupper Savara's lead drug filing - pharmaphorum
Savara Inc. Securities Fraud Class Action Lawsuit Pending: - GlobeNewswire
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) - BioSpace
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo
Foreign Language Equivalents
Foreign Language Equivalents of 'savara'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
savaar,   sacara,   saavra,   savaea,   savar,   asvara,   savra,   savata,   saara,   svara,   aavara,   savarra,   savaa,   sabara,   savvara,   savsra,   savaara,   saavara,   ssvara,   savaraa,   ssavara,   davara,   savars,   avara,   savraa,   svaara
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z